Rede D'Or stock trades around recent range as hospital group grows revenue and profit
Published on 07/23/2026 at 14:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rede D'Or São Luiz S.A. (ISIN BRRDORACNOR8) is one of Brazil's largest private hospital operators, and Rede D'Or stock represents a key healthcare exposure on the local market. As of 30 April 2024, the group reported a market capitalization in the tens of billions of Brazilian real, underpinned by double digit revenue growth and ongoing margin recovery. For investors, the latest full-year numbers and leverage trajectory frame the current risk-reward.
Revenue up about 16 percent in 2023
According to the company’s published annual information for fiscal 2023, Rede D'Or generated approximately BRL 30 billion in net revenue in 2023, up around 16 percent from roughly BRL 25.9 billion in 2022. This growth was driven by organic expansion of existing hospital units, higher patient volumes in key metropolitan regions, and the consolidation of acquisitions executed over the past two years.
In its 2023 figures, the group reported earnings before interest, taxes, depreciation, and amortization (EBITDA) in the range of BRL 7 billion, compared with approximately BRL 6 billion in 2022, implying EBITDA growth of roughly 17 percent year on year. The EBITDA margin thus improved modestly, rising from close to 23 percent in 2022 to about 23.5 percent in 2023, as management focused on efficiency measures, case mix optimization, and procurement synergies. Net income attributable to shareholders was reported in the ballpark of BRL 2.5 billion for 2023, noticeably higher than the roughly BRL 2.1 billion recorded in 2022, reflecting both operating leverage and lower per-unit financing costs despite a still elevated domestic interest-rate environment.
Hospital expansion and operating metrics
Rede D'Or’s published operational data for 2023 shows the group operating more than 70 hospitals across Brazil’s major urban centers, with total installed capacity exceeding 11,000 beds. Compared with 2022, the bed count increased by several hundred units, partially due to greenfield projects and partially due to the integration of acquired hospitals in regions such as São Paulo and Rio de Janeiro. The occupancy rate across the network remained high, with internal data pointing to average occupancy levels around the mid- to high-seventies percent range for 2023, broadly stable versus 2022, which supports revenue visibility.
On the payer mix side, Rede D'Or continued to derive the majority of its revenue from private health-insurance plans and corporate agreements, with a smaller portion from direct-pay patients. Management data for 2023 indicated that revenue from high-complexity procedures and intensive care continued to grow faster than lower-complexity services, helping sustain the EBITDA margin. The integration of recently acquired oncology clinics and diagnostic centers has also contributed to ancillary revenue streams, with non-hospital services accounting for a growing minority share of total revenue compared to the prior year.
Average revenue per bed increased year on year in 2023, reflecting both inflationary pricing adjustments and an improved case mix. Internal metrics pointed to low double digit growth in revenue per bed relative to 2022, broadly consistent with the headline revenue expansion. For investors, these operating indicators signal that the expansion strategy has not materially diluted per-unit economics so far.
Leverage trends and interest burden
Rede D'Or’s balance-sheet metrics show that the expansion has been financed partly through debt, which remains an important consideration for Rede D'Or stock. At the end of 2023, the company reported gross debt of roughly BRL 40 billion and cash and cash equivalents of close to BRL 10 billion, resulting in net debt in the region of BRL 30 billion. This represented a modest increase versus 2022 net debt levels, reflecting continued investment in new hospitals, equipment, and acquisitions.
Using the reported EBITDA for 2023, the net-debt-to-EBITDA ratio stood around 4.3 times, slightly higher than the roughly 4.1 times reported for 2022. The incremental leverage is mainly due to the timing of capital expenditure and acquisition payments, while EBITDA benefits from synergies materialize over time. Interest expense remained significant because of domestic interest rates, and the company’s 2023 accounts show financial expenses in the range of BRL 3 billion, similar to the prior year, underscoring the sensitivity of net profit to Brazil’s monetary policy.
Management has communicated medium-term intentions to gradually reduce leverage by prioritizing cash generation, moderating the pace of large-scale acquisitions, and optimizing the maturity profile of borrowings. For holders of Rede D'Or stock, the interplay between growth investments and deleveraging remains central to valuation discussions, especially as a sizeable portion of debt is linked to local floating-rate benchmarks.
Profitability, cash flow, and dividends
Rede D'Or’s 2023 free cash flow metrics, as disclosed in its financial information, show operating cash flow of around BRL 6 billion and capital expenditures approximating BRL 3 billion, resulting in free cash flow before acquisitions in the neighborhood of BRL 3 billion. Compared with 2022, free cash flow improved, aided by stronger EBITDA and working-capital discipline, although acquisition spending continues to absorb a meaningful portion of cash resources.
In its shareholder communications for 2023, the company indicated dividend distributions on the order of BRL 0.40 per share, representing a payout that balances returns to shareholders with reinvestment needs. Relative to the prior year, the total cash dividends increased, in line with higher net income, but the payout ratio remained moderate to preserve financial flexibility. For Rede D'Or stock, the combination of earnings growth and dividends offers a total-return profile that is closely watched by local institutional investors.
Margin analysis across the hospital network shows that the group has been able to stabilize adjusted EBITDA margins after a period of pandemic-related volatility. In several large units, the 2023 adjusted EBITDA margin exceeded 25 percent, aided by a focus on high-complexity services and negotiated pricing with private health-insurance partners. However, newly opened or acquired hospitals tend to have lower initial margins, and internal figures demonstrate a margin convergence process that typically takes several years.
Shares trade in line with recent valuation multiples
Rede D'Or stock is primarily listed on the B3 exchange in São Paulo under the ticker B3: RDOR3. As of 30 April 2024, publicly available quote data showed RDOR3 trading in the region of BRL 32 per share, broadly within its recent trading range over the preceding months. At that price level, the implied 2023 price-to-earnings ratio stood in the low twenties, based on reported net income, and the enterprise-value-to-EBITDA multiple was in the low double digits.
Relative to other listed Brazilian healthcare and diagnostic groups, these valuation metrics place Rede D'Or stock at a premium, reflecting its scale, diversified footprint, and perceived quality of assets, but not at extreme levels by historical standards. For example, using approximate numbers for 2023, Rede D'Or’s EV/EBITDA multiple is several turns higher than smaller peers but close to the range seen for high-growth healthcare platforms in prior years. Investors monitoring the stock weigh this premium against the continued potential for revenue growth and margin expansion.
Over the twelve months to 30 April 2024, RDOR3 delivered a positive total return, with the share price rising by a mid-single-digit percent and dividends adding to that performance. This outcome compares favorably with some broader Brazilian equity indices that exhibited more modest gains over the same period, suggesting that the market has rewarded the company’s execution in consolidating the private hospital sector.
More on Rede D'Or financials
For investors who want to study the detailed hospital-level performance, including occupancy metrics, payer mix, and capex plans, Rede D'Or’s filings and presentations provide extensive data.
Oncology and complex care services
Beyond general hospital services, Rede D'Or has developed a strong presence in oncology and complex care, which are important for both patient outcomes and profitability. The company has been expanding specialized cancer-treatment centers, integrating them into its hospital network to offer multidisciplinary care. In its 2023 reports, management highlighted growth in oncology-related procedures, which contributed to the overall revenue increase, although specific segment numbers were not broken out in full detail for every unit.
Complex surgeries, intensive-care services, and advanced diagnostic procedures also represent a crucial component of the group’s case mix. These services typically carry higher reimbursement levels and require substantial investment in equipment and specialist staff. Rede D'Or’s continued focus on such complex care helps differentiate its hospitals in competitive urban markets and supports the gradual improvement in margin metrics over time.
Rede D'Or stock reflects growth and leverage balance
At an indicative price of around BRL 32 per share for RDOR3 as of 30 April 2024, Rede D'Or stock encapsulates a balance between attractive growth prospects and the risks associated with leverage and integration. The company’s approximate BRL 30 billion of net revenue in 2023, up about 16 percent from 2022, and EBITDA near BRL 7 billion, up roughly 17 percent year on year, underline the strength of the underlying business. At the same time, net debt around BRL 30 billion and a net-debt-to-EBITDA ratio in the low single-digit multiples mean that cash generation and capital-allocation decisions will remain under close scrutiny.
For investors focusing on Brazil’s healthcare sector, Rede D'Or offers exposure to a large-scale hospital platform with diversified regional coverage and an expanding portfolio of specialized services. The company’s ability to sustain double digit revenue growth while gradually improving margins and managing leverage will likely be a central theme in future earnings discussions and could shape the market’s view on valuation.
Rede D'Or stock at a glance
- Company: Rede D'Or São Luiz S.A.
- ISIN: BRRDORACNOR8
- Ticker: B3: RDOR3
- Trading venue: B3 São Paulo
- Price (as of 30 April 2024, 17:00 BRT): 32.00 BRL
- Market capitalization: approximately 60,000,000,000 BRL (as of 30 April 2024)
- Sector / Industry: Healthcare / Hospitals
- Index membership: Ibovespa
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
